PMID- 8124252
OWN - NLM
STAT- MEDLINE
DCOM- 19940408
LR  - 20131121
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 12 Suppl 3
DP  - 1993
TI  - Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by 
      counterflow centrifugation.
PG  - S2-6
AB  - Eighty consecutive patients were transplanted with human leukocyte antigen 
      (HLA)-identical sibling marrow for acute myelogenous leukemia (AML, N = 29), 
      acute lymphoid leukemia (ALL, N = 23), or chronic myelogenous leukemia (CML, N = 
      28). Donor marrow was depleted of lymphocytes using counterflow centrifugation. 
      Median age of the recipients was 31 years. Pretransplant conditioning consisted 
      of cyclophosphamide and fractionated total body irradiation (TBI). Graft failure 
      occurred in 4 of 77 evaluable patients (5%). The probability of acute 
      graft-versus-host disease (GVHD) > or = grade 2 at day 100 after transplantation 
      was 15%. The projected 3-year estimate of extensive chronic GVHD was 12%. The 
      projected 3-year probability of relapse was 30% in transplants for AML in first 
      complete remission (CR1), 35% after transplantation for ALL in CR1, and 38% after 
      transplantation for CML in first chronic phase (CP1). The projected 3-year 
      probability of leukemia-free survival (LFS) was 56% after transplantation for 
      AML-CR1, 42% in patients transplanted for ALL-CR1, and 49% after transplantation 
      for CML-CP1. The chance of relapse was significantly reduced in a cohort of 72 
      standard risk patients conditioned with a regimen intensified by the addition of 
      anthracyclines. This resulted in DFS at 4 years after BMT of 63% compared to 39% 
      in a historical control group. Enrichment of the donor marrow with NK-cells did 
      not increase the incidence of GVHD, but did neither decrease the relapse rate 
      after BMT. In bone marrow transplantation for leukemia, counterflow 
      centrifugation is a useful technique for the prevention of GVHD. Further efforts 
      should be made to reduce relapse-rate, particularly in high risk patients.
FAU - De Witte, T
AU  - De Witte T
AD  - Department of Internal Medicine, University Hospital Nijmegen, The Netherlands.
FAU - Schattenberg, A
AU  - Schattenberg A
FAU - Preijers, F
AU  - Preijers F
FAU - Raymakers, R
AU  - Raymakers R
FAU - Muus, P
AU  - Muus P
FAU - Wessels, J
AU  - Wessels J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - Bone Marrow/pathology
MH  - Bone Marrow Transplantation/*methods/pathology
MH  - Centrifugation/methods
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/therapeutic use
MH  - Graft vs Host Disease/epidemiology/prevention & control
MH  - Humans
MH  - Incidence
MH  - Killer Cells, Natural/pathology
MH  - Leukemia, Myeloid, Acute/epidemiology/*therapy
MH  - Lymphocyte Depletion
MH  - Middle Aged
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology/*therapy
MH  - Recurrence
MH  - Risk Factors
MH  - Survival Rate
MH  - T-Lymphocytes/pathology
MH  - Transplantation, Homologous
MH  - Whole-Body Irradiation
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Bone Marrow Transplant. 1993;12 Suppl 3:S2-6.